The mammalian target of rapamycin (mTOR) pathway plays important roles in regulating nutrient metabolism and promoting the growth and survival of cancer cells, which exhibit increased glycolysis for ATP generation. In this study, we tested the hypothesis that inhibition of the mTOR pathway and glycolysis would synergistically impact the energy metabolism in cancer cells and may serve as an effective therapeutic strategy to kill malignant cells. Using human lymphoma cells and leukemia cells, we demonstrated that the combination of rapamycin, an mTOR inhibitor, with a glycolytic inhibitor produced synergistic cytotoxic effect, as evidenced by apoptosis and cell growth inhibition assays. Mechanistic studies showed that inhibition of the mTOR pathway by rapamycin alone sufficiently suppressed the phosphorylation of the downstream molecules p70S6K and 4E-BP-1, but only caused a moderate cytostatic effect. Combination of mTOR inhibition and blockage of glycolysis synergistically suppressed glucose uptake and severely depleted cellular ATP pools, leading to significant enhancement of cell killing. In contrast, combination of rapamycin and ara-C did not increase cytotoxicity in vitro. Our findings suggest that targeting mTOR pathway in combination with inhibition of glycolysis may be an effective therapeutic strategy for hematological malignancies. This mechanismbased drug combination warrants further investigation in preclinical and clinical settings.
Introduction
Generation of ATP is an essential metabolic process through which cells obtain their energy supply to maintain normal functions. Under aerobic conditions, mammalian cells can generate ATP through two metabolic pathways: glycolysis in the cytosol and oxidative phosphorylation in the mitochondria (respiration). ATP generation through mitochondrial respiration is more energy efficient (one glucose yields 36 ATP) than glycolysis (one glucose yields 2 ATP), and thus is a preferred pathway for the normal cells to generate energy supply. However, cancer cells including leukemia cells seem to have a fundamental change in their energy metabolism and exhibit increased dependency on glycolytic pathway for ATP generation. This metabolic alteration is known as the Warburg effect and has been consistently observed in a variety of human cancers, although it remains controversial whether the underlying mechanism is mainly due to inherent metabolic alterations in cancer cells or due to anaerobic environment in the tumor tissues. [1] [2] [3] The metabolic difference between the normal cells and cancer cells provide a biochemical basis for the design of therapeutic strategies to preferentially kill cancer cells. One strategy is to inhibit glycolysis and thus preferentially impact energy metabolism in cancer cells. Recently, there have been significant interests in this research area. For instance, several glycolytic inhibitors that target key glycolytic enzymes have been tested for their anticancer activity in vitro and in vivo. [4] [5] [6] [7] [8] Such a metabolic intervention seems to produce encouraging results, at least in experimental model systems.
Another strategy to impact cancer cell energy metabolism is to target the regulatory mechanisms that affect the expression or functions of protein molecules that are directly or indirectly involved in nutrient metabolism. The mammalian target of rapamycin (mTOR) pathway plays an important role in nutrient uptake, regulation of energy metabolism and cell proliferation, and promoting cancer cell survival. [9] [10] [11] [12] The critical functions of mTOR have led to the development of a number of novel compounds that target the mTOR pathway. CCI-779, RAD001, and AP-23573 are examples of this class of compounds currently in clinical trials for cancer treatment. 13, 14 These new compounds, like their parental compound rapamycin, directly target mTOR and effectively affect the function of this pathway and cause alterations in cellular metabolism and survival signaling. Clinical results suggest that these mTOR inhibitors are generally well tolerated and may induce prolonged stable disease or tumor regression in some patients. [13] [14] [15] Owing to the relatively low cytotoxic activity of the mTOR inhibitors, it seems logical to use this class of compounds in combination with other anticancer agents to achieve better therapeutic outcomes. Thus, it is important to further investigate the detailed mechanisms by which mTOR influences cellular metabolism, proliferation, and response to drug treatment, and to test and evaluate best drug combination regimens based on mechanisms of drug action to achieve optimal anticancer activity.
The present study evaluated the in vitro cytotoxic activity of the mTOR inhibitor rapamycin in combination with a new glycolytic inhibitor 3-bromo-2-oxopropionate-1-propyl ester (3-BrOP) in human leukemia and lymphoma cells. 3-BrOP is a cell permeable ester of 3-bromopyruvate (3-BrPA). Once inside the cells, 3-BrOP is readily hydrolyzed by cellular esterase to release 3-BrPA, which is known to potently inhibit glycolysis by inactivating hexokinase, a key enzyme responsible for the first step in the glycolytic pathway. 4, 5, 8, 16 Based on this mechanism of action, we hypothesized that combination of 3-BrOP with rapamycin would severely abolish ATP generation in cancer cells that are more dependent on glycolysis for energy production. The effect of rapamycin and ara-C combination was also evaluated in this study for comparison. We demonstrated that combination of rapamycin and 3-BrOP was highly synergistic in killing leukemia and lymphoma cells. These two compounds effectively depleted cellular ATP, and caused dephosphorylation of the mTOR downstream target molecules P70S6K and 4E-BP-1. In contrast, rapamycin did not significantly enhance the activity of ara-C. Our study suggests that while combination of mTOR inhibitors with ara-C may not be an effective therapeutic regimen, combination of mTOR inhibitors with glycolytic inhibitors appears promising, and warrants further investigation.
Materials and methods

Chemicals and reagents
Rapamycin was purchased from LC Laboratories (A division of PKC Pharmaceutical Inc., Woburn, MA, USA). 3-Bromo-2-oxopropionate and 1-propanol were purchased from Sigma (St Louis, MO, USA). 3-Bromo-2-oxopropionate-1-propyl ester (3-BrOP) was synthesized by esterification of 3-bromo-2-oxopropionate with 1-propanol at a 1:4 molar ratio under acidic condition, followed by neutralization with sodium carbonate and evaporation of the excess 1-propanol under vacuum. [ 3 H]-2-deoxyglucose was purchased from Amersham (Piscataway, NJ, USA). Rabbit phospho-p70S6K (Thr389) antibody, phosphop70S6K (Thr421/Ser424) antibodies, phospho-4E-BP1(Thr37/46) antibody, mouse anti-pBAD (S112), and rabbit polyclonal anti-BAD antibodies were purchased from Cell Signaling Technology Inc. (Beverly, MA, USA).
Cells and cell cultures
Human lymphoma cell line Raji and leukemia cell line HL-60 were routinely maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) in a tissue culture incubator at 371C in a humidified atmosphere with 5% CO 2 . The cultured cells were regularly split and maintained in the exponentially growing phase. Cells were diluted with fresh culture medium and incubated overnight before they were used in experiments.
Assays of cell growth and cytotoxicity
Cell growth inhibition was determined by direct counting of the cells after they were treated with rapamycin, 3-BrOP, or their combination. A Coulter Z 2 Particle Count & Size Analyzer was used to determine cell counts at 24, 48, and 72 h after drug incubation. Apoptosis was measured by flow cytometric analysis of cells stained with annexin V-FITC and propidium iodide (PI). Cells were treated with the indicated compounds under various incubation conditions as described in the figure legends. The samples were collected, washed with cold PBS, and then suspended in annexin-V-binding buffer. The cells were stained with annexin V-FITC for 15 min at room temperature, washed, and then stained with PI. The samples were analyzed using a FACSCalibur flow cytometer equipped with CELLQuestPro software (Becton-Dickinson, San Jose, CA, USA).
Measurement of glucose uptake and cellular ATP pool
After cells were treated with rapamycin and 3-BrOP under the desired conditions, cellular glucose uptake was measured by incubating the cells in glucose-free RPMI 1640 media with 0.2 mCi/ml of [ 3 H]-2-deoxyglucose (specific activity, 40 Ci/ mmol) for 60 min. After the samples were washed three times with cold PBS, the radioactivity in the cell pellets was quantified by liquid scintillation counting. To determine the effect of drug incubation on cellular ATP pool, cells were incubated with various concentrations of 3-BrOP and/or rapamycin for the indicated time intervals. Intracellular nucleotides were extracted from the cells with 0.4 N of perchloric acid (PCA) for 10 min in ice-bath, neutralization with concentrated KOH to pH 7.0, and analyzed by HPLC analysis as described previously. 4, 17 The intracellular ATP contents were calculated using the ATP standard curve generated under identical HPLC conditions, and normalized by equal cell number. The relative cellular ATP levels were expressed as percent of the control cells.
Western blot analysis
Protein lysates were prepared from the control and drug-treated cells, and separated by electrophoresis on 10% SDS-PAGE. After the proteins were transferred to nitrocellulose membranes, they were blotted for molecules of interest, using specific antibodies against p-p70S6K (Thr389), p-p70S6K (Thr421/Ser424), p-4E-BP1 (Thr37/46), pBAD (S112), and total BAD. The primary antibodies were dilute at 1:1000 unless indicated otherwise. The bound primary antibodies were detected using appropriate horseradish peroxidase-conjugated secondary antibodies, followed by detection with a SuperSignal enhanced chemiluminescence kit (Pierce, Rockford, IL, USA). For sequential blotting, the membranes were stripped with a stripping buffer (Pierce, Rockford, IL, USA) followed by reblotting with proper antibodies.
Results and discussion
Inhibition of mTOR and glycolysis leads to synergistic cytotoxicity in lymphoma and leukemia cells Since the mTOR pathway plays an important role in promoting cellular nutrient metabolism and cell growth, and functions to enhance cell survival downstream of the PI3K/Akt pathway, we postulated that a simultaneous inhibition of mTOR and glycolysis, which serves as a major metabolic pathway for ATP generation in cancer cells, would severely impact cellular energy metabolism and have a potent cytotoxic effect against malignant cells. To test this possibility, we used rapamycin as an agent to inhibit mTOR, and 3-BrOP to inhibit glycolysis. 3-BrOP is a cell permeable ester that is hydrolyzed to release 3-BrPA, a potent inhibitor of the glycolytic enzyme hexokinase. 4, 5, 8, 16 As shown in Figure 1a , treatment of human lymphoma cells (Raji) with 30 mM 3-BrOP resulted in 19 and 49% apoptosis at 24 and 48 h, respectively, as measured by flow cytometry analysis after the cells were double-stained with annexin-V and PI. Combination of 3-BrOP with 100 ng/ml rapamycin, which by itself alone did not induce significant apoptosis (4.8%), led to a substantial increase of apoptosis, with 38 and 79% apoptotic cells at 24 and 48 h, respectively.
The above observations prompted us to use a formal drug combination analysis to determine if rapamycin and 3-BrOP have a synergistic effect. Both Raji cells and HL-60 leukemia cells were used for this study. Cells were treated with various concentrations of 3-BrOP in the presence of a fixed concentration of rapamycin (100 ng/ml) for 24 h, and the percentage of apoptotic cells was quantitated by flow cytometry analysis using annexin-V/PI double staining. As illustrated in Figure 1b and c, the nontoxic concentration of rapamycin (100 ng/ml) significantly potentiate the cytotoxic activity of 3-BrOP at most concentrations tested in both cell lines. We then used the median-effect analysis program described by Chou and Hayball 18 to calculate the drug combination index (CI). In this analysis, an additive effect would produce a CI value of 1, whereas synergistic and antagonistic effects would give CI values of o1 and 41, respectively. As shown in Figure 1d , the CI values were o1, indicating that the rapamycin and BrOP produced synergistic cytotoxicity when they were used together.
A different assay was then used to further confirm the synergy between rapamycin and 3-BrOP. Raji cells were treated with 30 mM 3-BrOP, 100 ng/ml rapamycin, or their combination, and the numbers of cells were directly counted for consecutive 3 days, using a Coulter Z 2 Particle Count & Size Analyzer. As illustrated in Figure 2 , either 3-BrOP or rapamycin alone caused a moderate delay of the cell growth under these experimental conditions, with approximate 35% decrease in cell numbers in each case. It is worth noting that the same concentration of rapamycin (100 ng/ml) did not cause acute cell death in apoptosis assay (Figure 1 ), but caused a 35% decrease in cell growth, consistent with the cytostatic effect of rapamycin in cells that preserve their cell cycle checkpoint function. 19, 20 Importantly, combination of these two agents at the sub-toxic concentrations exhibited an almost complete inhibition of cell growth (Figure 2 ), confirming their synergistic activity.
Rapamycin exhibits no significant effect on ara-C cytotoxic activity
Based on the ability of rapamycin to potentiate the activity of 3-BrOP in human lymphoma and leukemia cells, we then tested if rapamycin could be used to enhance the cytotoxic activity of ara-C, an effective agent widely used in clinical treatment of leukemia and certain lymphoma. Flow cytometry analysis showed that rapamycin did not significantly affect the cytotoxic activity of ara-C in Raji cells (Figure 3a) . For instance, ara-C at the concentration range of 0.5-1 mM induced apoptosis in 20-35% of the cells. Addition of 100 ng/ml rapamycin led to a similar percent of apoptotic cells (Figure 3b ). This is in contrast to the results from the 3-BrOP experiments, in which the same concentration of rapamycin increased apoptosis from 19 to 38% Growth inhibition by rapamycin and 3-BrOP in Raji cells. Cells in exponentially growing phase were treated with 100 ng/ ml rapamycin at time 0, and 3-BrOP (30 mM) was added 18 h later. Cell culture was continued for up to 72 h, and cell numbers were directly counted at the indicated time intervals, using a Coulter Z 2 Particle Counter & Size Analyzer to determine the total particle numbers.
( Figure 1a) . Thus, it appears that combination of rapamycin and ara-C may not significantly increase cell killing. Based on this observation, we focused our studies on combination of rapamycin with 3-BrOP to further examine the possible mechanisms with respect to ATP metabolism and the relevant molecular events.
It is of interest to note that the cell death process induced by ara-C appeared somewhat different from that induced by 3-BrOP. Ara-C seems to induce typical apoptosis, with a majority of dead cells showing positive staining with annexin-V but negative for PI, and a portion of cells exhibiting secondary necrosis (double positive for annexin-V and PI) after 30 h incubation (Figure 3a) . Addition of rapamycin did not cause any significant change in the dead cell subpopulations. In contrast, most of the dead cells induced by 3-BrOP were stained double positive for both annexin-V and PI (Figure 1a) , indicating phosphatidylserine exposure on the cell surface (positive annexin-V reactivity) and a significant damage to the cellular membrane integrity (positive PI staining). The exact mechanism responsible for this difference is unclear at the present time. It is possible that the severe ATP depletion induced by 3-BrOP (see below) may compromise the ability of cells to maintain their membrane integrity, and that rapamycin significantly enhances this action of 3-BrOP (Figure 1a) . The dead cell population in the samples treated with 3-BrOP and rapamycin likely contained apoptotic and necrotic cells.
Combination of rapamycin and 3-BrOP causes a synergistic depletion of cellular ATP
HPLC analysis was then used to determine cellular ATP pool in an attempt to understand the biochemical basis of the synergistic activity of rapamycin and 3-BrOP. Raji cells were treated with various concentrations of 3-BrOP in the presence and absence of rapamycin (100 ng/ml) for 6 h, and cellular ATP and other nucleotide pools were measured by HPLC analysis as described in Materials and methods. As illustrated in Figure 4 , treatment of Raji cells with 3-BrOP resulted in a concentration-dependent decrease in cellular ATP pool. Of note, the decrease of ATP pool occurred at 6 h after incubation with 3-BrOP and was well before the appearance of apoptosis, suggesting that the ATP pool reduction was not a consequence of cell death. The HPLC analysis also revealed that subsequent to depletion of ATP pool Effect of rapamycin and ara-C on apoptotic response in Raji cells. (a) Raji cells were treated with rapamycin (100 ng/ml, 48 h) and ara-C (0.5 and 1 mM, 30 h), alone or in combination as indicated. In case of drug combination, cells were first treated with rapamycin for 18 h before addition of ara-C and incubated for an additional 30 h. Apoptosis were analyzed by annexin/PI assay as described in Materials and methods. Representative flow cytometry analyses are illustrated in (a), and quantitative data are shown in (b). Solid bars, cells treated with ara-C alone; hatched bars, cells treated with ara-C plus rapamycin. There was no significant statistical difference between % apoptosis in cells treated with ara-C alone and the combination ara-C and rapamycin. by 3-BrOP, there was a secondary depletion of other nucleotide pools (data not shown).
Incubation of Raji cells with 100 ng/ml rapamycin alone for 24 h did not cause any detectable change in cellular ATP pool (Figure 4) . However, preincubation of Raji cells with this concentration of rapamycin for 18 h followed by a 6-h treatment with 3-BrOP significantly enhanced the depletion of cellular ATP. Because this ATP depletion occurred before apoptosis became detectable, it seems that the enhancement of ATP depletion might be a biochemical mechanism by which rapamycin promote the cytotoxic effect of 3-BrOP. This led us to further seek possible mechanisms contributing to this increased depletion of ATP pool.
Rapamycin significantly enhances the ability of 3-BrOP to inhibit glucose uptake Recent studies suggest that the mTOR pathway may play an important role in promoting cellular nutrient uptake and cell growth. 10, 21 We reasoned that rapamycin, by inhibiting mTOR, might compromise the ability of cellular uptake of glucose and thus enhance ATP depletion by 3-BrOP. To test this possible mechanism, we used [
3 H]-deoxyglucose to evaluate the effect of 3-BrOP and rapamycin on glucose uptake. Incubation of Raji cells with 30 and 50 mM 3-BrOP for 2 h caused a decrease of glucose uptake by 33 and 71%, respectively ( Figure 5 ). This acute inhibition of glucose uptake was likely due to a direct inhibition of hexokinase by 3-BrPA leading to a failure in glucose phosphorylation and subsequent block of glucose flow into the glycolytic pathway. 4, 5 When Raji cells were treated with rapamycin (100 ng/ml) for 20 h, there was only a slight decrease (6%) in glucose uptake ( Figure 5 ), suggesting that this compound alone caused a minimum disturbance of glucose uptake under the experimental conditions. However, when cells were pretreated with rapamycin for 18 h followed by incubation with 3-BrOP for 2 h, glucose uptake was severely inhibited. The degree of inhibition was significantly greater than 3-BrOP alone ( Figure 5 ). For instance, in the presence of rapamycin, 30 mM of 3-BrOP caused a 70% inhibition of glucose uptake, compared to a 33% inhibition by 30 mM of 3-BrOP alone. Similarly, combination of 100 ng/ml of rapamycin and 50 mM of 3-BrOP led to 94% inhibition of glucose uptake, whereas 50 mM of 3-BrOP alone caused a 71% inhibition. It appears that inhibition of mTOR by rapamycin compromised the ability of cells to uptake glucose when the glycolytic pathway was inhibited by 3-BrOP.
Effect of rapamycin and 3-BrOP on phosphorylation of molecules downstream of mTOR
Since rapamycin at the concentration of 100 ng/ml alone did not exhibit any significant effect on the biochemical end points in the experiments described above, it is necessary to test if this concentration of rapamycin inhibits its molecular target in Raji cells. The phosphorylation of p70S6K and 4E-BP1, two target molecules of mTOR, was examined as indications of mTOR inhibition. 11, 22 As shown in Figure 6 , incubation of Raji cells with 100 ng/ml of rapamycin completely abolished the phosphorylation of p70S6K at Thr389, and a decrease in phosphorylation of p70S6K at Thr421/Ser424 and 4E-BP-1 at Ser65 (lane 2). These data suggest that this concentration of rapamycin indeed inhibited its molecular target in the cells. Interestingly, a high concentration of 3-BrOP (40 mM, lane 4) also showed some inhibition on phosphorylation of P70 S6K at Thr389 (but not at Thr421/Ser424) and 4E-BP-1 at Ser65. Combination of rapamycin and 3-BrOP appeared to cause further decrease of 4E-BP-1 phosphorylation at Ser65, but not at Thr421/Ser424 of P70 S6K. The biological significance of this combined effect on protein phosphorylation is unclear at the present time.
Our previous study showed that phosphorylation of BAD, a Bcl-2 family member that plays an important role in integrating Inhibition of cellular glucose uptake by rapamycin and 3-BrOP. Cells were first treated with rapamycin (100 ng/ml) for 18 h, and then incubated with the indicated concentrations of 3-BrOP for an additional 2 h. The samples were washed with fresh warm medium, and 5 Â 10 6 cells were resuspended in 5 ml RPMI 1640 media (glucose free) containing 0.2 mCi/ml [ Effect of rapamycin and 3-BrOP on phosphorylation of the mTOR downstream targets. Raji cells were treated with Rapamycin (100 ng/ml) for 24 h, and/or the indicated concentrations of 3-BrOP for 6 h. In case of drug combination, cells were first incubated with rapamycin for 18 h, and then with 3-BrOP for an additional 6 h. Equal amounts of cellular protein extracts were resolved by SDS-PAGE, and blotted for p-p70S6K (Thr389), p-p70S6K (Thr421/Ser424), p-4E-BP-1 (Ser65), p-BAD (Ser112), and total BAD protein, using respective antibodies. b-Actin was also blotted as protein loading control. glycolysis and apoptosis, was significantly decreased at Ser112 during apoptosis induced by the glycolytic inhibitor 3-BrPA. 4 We examined the effect of rapamycin on BAD phosphorylation in 3-BrOP-treated cells. As illustrated in Figure 6 , the subtoxic concentration of 3-BrOP (20 mM) did not reduce BAD phosphorylation at Ser112 (lane 3), where the toxic concentration of 3-BrOP (40 mM) caused a substantial decrease of BAD phosphorylation (lane 4). The presence of rapamycin completely abolished BAD phosphorylation in cells treated with 40 mM of 3-BrOP (lane 6), consistent with the synergistic effect of these two compounds.
In summary, our studies demonstrated that combination of rapamycin and 3-BrOP resulted in a synergistic cytotoxic effect against human lymphoma and leukemia cells, and suggests that targeting the mTOR pathway with a simultaneous inhibition of glycolysis may be an effective therapeutic strategy for the treatment of hematological malignancies. Although rapamycin at the concentration of 100 ng/ml was able to inhibit the molecular target in the cells and sufficiently suppress the phosphorylation of the molecules downstream of mTOR including P70 S6K and 4E-BP-1, such inhibition of the mTOR pathway alone only led to a moderate cytostatic effect without significant cytotoxicity. In contrast, inhibition of glycolytic pathway significantly blocked ATP generation in cancer cells, which are highly dependent on glycolysis for energy supply, and produced cytotoxic effect. Since the mTOR pathway plays an important role in promoting cellular nutrient uptake, cell growth and cell survival, combination of mTOR inhibition and blockage of glycolysis seems to be a mechanism-based strategy to severely impact cancer cell energy metabolism and effectively kill the malignant cells. Indeed, our data showed that combination of rapamycin and 3-BrOP synergistically suppressed glucose uptake and severely depleted cellular ATP pools, leading to synergistic cell killing. On the other hand, combination of rapamycin and ara-C appears not effective, and suggests that a simultaneous inhibition of mTOR pathway by rapamycin and suppression of DNA synthesis by ara-C may not lead to enhancement of cell killing. Our findings suggest that the use of an mTOR inhibitor such as CCI-779 or RAD001 in combination with a glycolytic inhibitor is a promising new therapeutic strategy and may have significant clinical implications in treatment of leukemia and lymphoma. Since the use of established leukemia cell lines have certain limitations such as metabolic adaptations during long-term cell culture and the associated changes in cell growth and proliferation, it is important in future studies to test this mechanism-based drug combination strategy in primary leukemia cells isolated from patients. Once the synergistic activity of the mTOR inhibitors and glycolytic inhibitors is verified in primary leukemia cells, this would warrant further investigation in vivo.
